BioAtla Inc.

7.95+1.34+20.27%Vol 8.82M1Y Perf -84.02%
Aug 11th, 2022 16:00 DELAYED
BID7.95 ASK8.00
Open6.87 Previous Close6.61
Pre-Market- After-Market7.77
 - -  -0.18 -2.26%
Target Price
35.20 
Analyst Rating
Strong Buy 1.00
Potential %
342.77 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/-81 
Value Ranking
★★★★     55.26
Insiders Value % 3/6/12 mo.
100/100/-97 
Growth Ranking
★★★     50.96
Insiders Shares Cnt. % 3/6/12 mo.
100/100/-71 
Income Ranking
 —    -
Price Range Ratio 52W %
14.28 
Earnings Rating
Market Cap298.25M 
Earnings Date
9th Aug 2022
Alpha-0.11 Standard Deviation0.21
Beta1.24 

Today's Price Range

6.729.15

52W Range

2.0143.61

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
101.78%
1 Month
98.75%
3 Months
232.64%
6 Months
10.72%
1 Year
-84.02%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BCAB7.951.340020.27
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-40 381.60
-39 848.00
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-71.36
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.70-0.77-10.00
Q01 2022-0.69-0.655.80
Q04 2021-0.72-0.6312.50
Q03 2021-0.92-0.6826.09
Q02 2021-0.56-0.90-60.71
Q01 2021-0.48-0.56-16.67
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.69
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume8.82M
Shares Outstanding37.52K
Shares Float26.52M
Trades Count52.48K
Dollar Volume68.80M
Avg. Volume1.99M
Avg. Weekly Volume3.98M
Avg. Monthly Volume1.20M
Avg. Quarterly Volume785.31K

BioAtla Inc. (NASDAQ: BCAB) stock closed at 7.95 per share at the end of the most recent trading day (a 20.27% change compared to the prior day closing price) with a volume of 8.82M shares and market capitalization of 298.25M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. BioAtla Inc. CEO is Jay M. Short.

The one-year performance of BioAtla Inc. stock is -84.02%, while year-to-date (YTD) performance is -59.5%. BCAB stock has a five-year performance of %. Its 52-week range is between 2.01 and 43.61, which gives BCAB stock a 52-week price range ratio of 14.28%

BioAtla Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 0.83, a price-to-sale (PS) ratio of 439.68, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -43.92%, a ROC of -51.53% and a ROE of -52.31%. The company’s profit margin is -%, its EBITDA margin is -39 848.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioAtla Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.69 for the next earnings report. BioAtla Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioAtla Inc. is Strong Buy (1), with a target price of $35.2, which is +342.77% compared to the current price. The earnings rating for BioAtla Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioAtla Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioAtla Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.32, ATR14 : 0.79, CCI20 : 389.11, Chaikin Money Flow : 0.30, MACD : 0.55, Money Flow Index : 97.30, ROC : 120.83, RSI : 70.14, STOCH (14,3) : 79.99, STOCH RSI : 1.00, UO : 63.74, Williams %R : -20.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioAtla Inc. in the last 12-months were: Christian Vasquez (Buy at a value of $150 914), Christian Vasquez (Sold 3 183 shares of value $79 532 ), Eric Sievers (Sold 8 019 shares of value $304 081 ), Guy Levy (Sold 1 093 418 shares of value $43 354 022 ), Jay M. Short (Buy at a value of $198 336), Jay M. Short (Option Excercise at a value of $139 446), Jay M. Short (Sold 77 608 shares of value $2 013 497 ), Lawrence J. Steinman (Sold 1 350 shares of value $48 339 ), Richard A. Waldron (Sold 17 932 shares of value $446 708 ), Scott A. Smith (Sold 38 217 shares of value $1 474 727 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

CEO: Jay M. Short

Telephone: +1 858 558-0708

Address: 11085 Torreyana Road, San Diego 92121, CA, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

Bearish Bullish

61%39%

TipRanks News for BCAB

Sun, 15 May 2022 13:20 GMT BioAtla (BCAB) Receives a Buy from J.P. Morgan

- TipRanks. All rights reserved.

Thu, 05 May 2022 10:35 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: BioAtla (BCAB), IVERIC bio (ISEE) and Acelrx (ACRX)

- TipRanks. All rights reserved.

Tue, 25 Jan 2022 10:17 GMT BioAtla, Inc. Updates 2 Key Risk Factors

- TipRanks. All rights reserved.

News

Stocktwits